Scancell Holdings Plc Professor Lindy Durrant receives Waldenström award
March 21 2019 - 3:02AM
RNS Non-Regulatory
TIDMSCLP
Scancell Holdings Plc
21 March 2019
21 March 2019
Scancell Holdings Plc
("Scancell" or the "Company")
Professor Lindy Durrant receives Waldenström award from the
Swedish Society of Oncology
Scancell Holdings plc, the developer of novel immunotherapies
for the treatment of cancer, is delighted to announce that
Professor Lindy Durrant, Scancell's Chief Scientific Officer, is to
receive the Swedish Society of Oncology's Waldenström award.
Professor Durrant will be presented with the award at the Swedish
Society of Oncology Annual Meeting on Thursday 21 March 2019 at
13:30 CET in Stockholm, Sweden, and will give an honorary lecture
to fellow society members. The theme of the lecture will be on
novel approaches to cancer vaccinations, including references to
both ImmunoBody(R) and Moditope(R) , Scancell's novel
immunotherapies for the treatment of cancer.
The Jan Waldenström award is presented for a successful career
in cancer research. Waldenström macroglobulinemia is a type of
non-Hodgkin lymphoma and is named after Jan Gösta Waldenström (17
April 1906-1 December 1996), the Swedish doctor of internal
medicine, who first described the disease.
Professor Lindy Durrant, co-founder and Chief Scientific Officer
of Scancell, is an internationally recognised immunologist in the
field of tumour therapy. She has worked for over 20 years in
translational research, developing products for clinical trials
including monoclonal antibodies and cancer vaccines. Lindy and her
team have developed a platform called ImmunoBody(R) , which uses
DNA encoding human antibodies engineered to express tumour
antigens, to stimulate potent killer T cells for the treatment of
melanoma and lung cancer. Her team is also the first group to show
that immune responses to stress induced modifications, the
Moditope(R) platform, induces strong anti-tumour responses. Lindy
also has a personal chair in cancer immunotherapy at the University
of Nottingham and has published over 200 original papers and
patents.
Professor Lindy Durrant, Chief Scientific Officer of Scancell,
said:
"I am honoured to have been awarded the prestigious Waldenström
award which recognises the research my group has undertaken and its
potential application to the treatment of cancer. I am proud to be
leading the research at Scancell, developing products that
stimulate the immune system to treat or prevent cancer recurrence
and for our work to be recognised by the Swedish Society of
Oncology."
For Further Information:
Scancell Holdings Plc
Dr John Chiplin, Chairman +44 (0) 20 3727 1000
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited
(Nominated Adviser and Corporate
broker)
Freddy Crossley/Emma Earl +44 (0) 20 7886 2500
FTI Consulting
Simon Conway/Natalie Garland-Collins +44 (0) 20 3727 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
parts of the cellular immune system. They can be used as
monotherapy or in combination with checkpoint inhibitors. This
platform has the potential to enhance tumour destruction, prevent
disease recurrence and extend survival.
-- SCIB1, the lead programme, is being developed for the
treatment of melanoma. A phase 1/2 clinical trial has so far
successfully demonstrated survival data of more than five
years.
-- SCIB2 is being developed for the treatment of non-small cell
lung cancer and other solid tumours. Scancell has entered into a
clinical development partnership with Cancer Research UK for
SCIB2.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents based on stress-induced
post-translational modifications (siPTM). It stimulates the
production of killer CD4 T cells which overcome the immune
suppression induced by tumours, allowing activated T cells to seek
out and kill tumour cells that would otherwise be hidden from the
immune system. Moditope(R) alone, or in combination with other
agents, has the potential to treat a wide variety of cancers.
-- Modi-1 is being developed for the treatment of solid tumours
including triple negative breast cancer, ovarian cancer and head
and neck cancer.
For further details, please see our website:
www.scancell.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRASEWFWSFUSEFD
(END) Dow Jones Newswires
March 21, 2019 03:02 ET (07:02 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2023 to Apr 2024
